Genfit stock hits SBF 120 bottom, weighed down by 33.7% loss in one month
The Lille-based biotech specializing in hepatic and metabolic diseases emerges as the worst-performing value in the SBF 120 this Thursday morning, extending a deterioration phase that began several weeks ago. The decline occurs in a European market itself weakened by rising bond yields, which weighs on growth stocks and biotechs.
Genfit bottom of the SBF 120 with a decline of 6.27% and -33.7% over one month
Genfit is down 6.27% during the session and is trading at 9.56 €, making it the steepest decline in the SBF 120 for the day. The monthly performance is heavy: -33.7% over one month, after peaking well above 14 € in August. Over the week, the correction has already reached 20.33%.
At this point, the security has erased a large portion of the spectacular rebound posted over one year (+205.6%), which had notably led it to join the CAC Mid 60 and SBF 120 indices of Euronext Paris following the annual review in September. Tuesday's session had already highlighted this fragility, with the security already emerging as the bottom performer of the index. The market context is not helping matters: the CAC 40 is down 0.8% during the session and the SBF 120 is moving in the same direction, amid bond yields under pressure following solid economic statistics in the eurozone.
A highly deteriorated technical configuration, half-yearly results expected on September 29
Technically, the situation is clearly bearish. The price is trading at 9.56 €, well below the 20-day moving average at 12.81 € (gap of -25.37%) and the 50-day moving average at 13.33 € (gap of -28.28%): both short and medium-term moving averages are acting as distant ceilings. The RSI at 28 reflects a marked oversold configuration, close to the 30 threshold, but without a confirmed rebound signal at this stage. The price remains slightly above the 200-day moving average at 9.38 € (gap +1.92%), which for now remains the only technical reference point still preserved to the downside.
Furthermore, according to statements consulted, two funds collectively hold 1.10% of capital sold short, a position that has increased by 1.10 percentage points in thirty days. This rapid rise in the bearish bet reflects increasing pressure on the security, even though the absolute level remains moderate. On the fundamentals side, when publishing first quarter 2026 results (May 21, 2026), the company had highlighted the favorable dynamics of Iqirvo royalties as a lever for margin strengthening. The next major event is scheduled for September 29, with the publication of 2026 half-year results.
